HALO Profile
Halozyme Therapeutics, Inc. operates as a prominent biopharmaceutical technology platform company with a global presence spanning the United States, Switzerland, Ireland, Belgium, Japan, and beyond. The company is renowned for its innovative ENHANZE drug delivery technology, leveraging a patented recombinant human hyaluronidase enzyme (rHuPH20). This technology facilitates the subcutaneous administration of injectable biologics, including monoclonal antibodies, therapeutic molecules, small molecules, and fluids, enhancing treatment options for various medical conditions.
The flagship product of Halozyme is Hylenex recombinant, formulated with rHuPH20, which aids in subcutaneous fluid administration to improve the dispersion and absorption of injected drugs in subcutaneous urography. Additionally, it enhances the resorption of radiopaque agents, optimizing diagnostic procedures. Halozyme Therapeutics also focuses on developing and advancing a robust pipeline of therapies. This includes collaborations and product developments such as Perjeta, RITUXAN HYCELA, MabThera SC for non-Hodgkin lymphoma and chronic lymphocytic leukemia (CLL), RITUXAN SC for CLL patients, and HYQVIA for immunodeficiency disorders.
Innovative therapies in Halozyme's pipeline include Tecentriq for non-small cell lung cancer, OCREVUS for multiple sclerosis, DARZALEX for amyloidosis, smoldering myeloma, and multiple myeloma, as well as nivolumab for solid tumors. Further advancements include ARGX-113 targeting the human neonatal Fc receptor, ARGX-117 for autoimmune diseases, and BMS-986179, an anti-CD-73 antibody, reflecting the company's commitment to addressing unmet medical needs through cutting-edge research and development.
Founded in 1998 and headquartered in San Diego, California, Halozyme Therapeutics continues to expand its collaborations with leading pharmaceutical companies like Roche, Pfizer, Janssen Biotech, AbbVie, Eli Lilly, Bristol-Myers Squibb, and others. These partnerships aim to explore small and large molecule targets for the treatment and prevention of HIV, underscoring Halozyme's strategic focus on advancing transformative therapies and pioneering drug delivery technologies in the biopharmaceutical industry.
|
